TOPBP1 and prostate cancer: Targeting CDC6 together with Chk1/2 inhibitor could suppress TopBP1-ATR-Chk1 signaling and increase phosphorylation of ATM, a biomarker of DNA damage, synergistically increasing the treatment efficacy in prostate cancer cells (Karanika et al., 2017).